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VARIABLE CHIMERISM, GRAFT-VERSUS-HOST DISEASE, AND 
TOLERANCE AFTER DIFFERENT KINDS OF CELL AND 
WHOLE ORGAN TRANSPLANTATION FROM LEWIS TO 
BROWN NORWAY RATS 1 
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The bidirectional paradigm of tolerance involving 
reciprocal host vs. graft and graft vs. host reactions 
was examined after Lewis (LEW) -- Brown Norway 
(BN) transplantation of different whole organs (liver, 
intestine, heart, and kidDey) or of 2.5 x lOB LEW leuko-
cytes obtained from bone marrow, spleen, lymph 
nodes, and thymus. The experiments were performed 
without immunosuppression or under 14 daily doses 
of postoperative tacrolimus, which were continued in 
weekly doses to 100 days in a "continuous treatment" 
subgroup, and to 27 days in a short treatment group. 
Without immunosuppression. all organs and cell sus-
pensions failed to engraft or were acutely rejected. 
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GVHD (usually fatal) was always caused when either 
the long or short treatment was used for recipients of 
intestinal grafts and cell suspensions of spleen and 
lymph nodes. In contrast, both immunosuppressive 
protocols allowed engraftment of bone marrow cells, 
liver, heart, and kidney without clinical GVHD, 
whereas thymus cell suspensions and small doses of 
whole blood neither engrafted nor caused GVHD. At 
100 days, now drug-free for 73 days, the liver, bone 
marrow, and heart recipients were tolerant in that 
they accepted all challenge LEW heart and/or liver 
grafts for 100 more days despite in vitro evidence of 
donor'specific reactivity (split tolerance). At 200 days, 
histopathologic studies of the challenge livers were 
normal no matter what the priming graft. However, 
the still-beating challenge hearts had a spectnun from 
normal to severe chronic rejection that defined the 
tolerogenicity of the original primary grafts: liver best 
-+ bone marrow next - heart least. Both the GVHD 
propensity and tolerogenicity in these experiments 
were closely associated with recipient tissue chimer-
ism 30 and 100 days after the experiments began. The 
tissue chimerism Willi invariably multilineage, but the 
GVHD outcome Willi IlIIsociated with T cell over-rep~ 
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sentation. These observations provide guidelines that 
should be considered in devising leukocyte augmenta-
tion protocols for human whole organ recipients. The 
results are discussed in relation to the historical tol-
erance studies of Billingham, Brent, and Medawar; 
Good; Monaco; and Calne. 
The persistence of micro chimerism in human whole organ 
recipients years or decades after transplantation (1, 2) re-
flects the migration long before of bone marrow-derived do-
nor leukocytes from the allografts (3, 4). We have postulated 
that these immunocompetent donor cells represent one limb 
of initially antagonistic but ultimately attenuated or abro-
gated host-versus-graft (HVG,* rejection) and graft-versus-
host (GVH) reactions (1-5) (Fig. 1). We describe here a study 
in rats of the HVG and GVH components of this two-way 
immunologic paradigm. The clinical and histopathologic ex-
pression of the two arms with and without immunosuppres-
sion was correlated with the quantity and quality of recipient 
tissue chimerism and with the development of donor-specific 
tolerance following transplantation from Lewis (LEW) do-
nors to Brown Norway (BN) recipients of different organs 
(intestine, liver, heart, kidney) and of different free leukocyte 
suspensions (bone marrow, lymph nodes, spleen, thymus, 
and blood). 
Although the results leave numerous questions unan-
swered about basic mechanisms, they cast light on 4 issues 
that are relevant to planning of clinical tolerance induction 
protocols: 0) The relative risk of producing clinical GVHD 
with the tranplantation of different organs and with infusion 
of a standardized dose of leukocytes obtained from various 
lymphoid organs, (2) the relative tolerogenicity of the paren-
chymal organs and the leukocyte suspensions, (3) correlation 
of 1 and 2 with the density and lineage profile of the chimer-
ism in recipient tissues and, (4) the relation to the quantity 
and lineage composition of chimerism to chronic rejection. 
MATERIALS AND METHODS 
Animals and transplant procedures. Male Lewis (LEW, RTll) and 
Brown Norway (BN, RTln) rats weighing 200-300 g were purchased 
as donors and recipients, respectively (Harlan Sprague Dawley, In-
dianapolis. IN). and maintained in conventional animal facilities. 
The kidney (6). small intestine (7), and liver allografts (8) were 
placed orthotopically after removal of the corresponding native or-
gan. The heart grafts were vascularized heterotopically in the abdo-
men (9). 
Leukocytes were washed from the bone marrow of tibias and 
femurs. The preliminary step of cell extraction from the spleen, 
lymph nodes. and thymus was by compression of fragments of the 
whole organs through a stainless steel mesh and filtration of the 
product through a nylon mesh. The cells were processed with RPM! 
1640 supplemented with 25 mM Hepes buffer. 2 mM L-glutamme, 50 
U/ml pemcillin. and 50 ~ml streptomycin lall from Gibco. Grand 
Island. NY). Trypan blue exclusion testing always showed >90% 
viability before intravenous injection into the penile vein of the BN 
recipients. The cell counts of the suspensions were determined 
\ 2.SX 10M per experiment). permitting a umform cell dose and there-
fore a meamngful comparison of eventual results. The cell dose was 
not quantItated in expenments mvolvmg 3 ml unaltered donor whole 
• AbbreV1ations: BN. Brown-Norway; GVH. graft-versus-host: 
GVHD. graft-versus-host-disease: G-CSF. granulocyte colony-stlmu-
lating factor: GM-CSF. granUlOcyte macrophage colony stimulating 
(actor: HVG. host-versus-graft: LEW. LeWls: MLR. mIxed lvrnpho-
cyte response: :Y1cA.b. monoclonal antibody. 
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FIGURE 1. Dualistic immune reactions of host.versus-graft (HVG) 
and graft-versus·host (GVH) in the two-way paradigm of trans plan-
tation immunology. Following the acute reaction, the evolution of 
tolerance of each leukocyte population to the other is seen as a 
low-grade stimulatory state that may wax and wane rather than a 
deletional one. 
blood infusion. However, spot samples ofbuffy coats from 3 ml blood 
had approximately 2.5-3 X 107 cells, or about 1/10 the dose ofthe cell 
suspensions. The leukoprofile of naive LEW as well as BN rats of the 
cell suspensions of the central lymphoid organs was reported in 
detail previously (10), and is summarized schematically for the LEW 
donor strain in Fig. 2. Although there were differences between the 
other oentral lymphoid organs, the bone marrow was dramatically 
different from all because of the large number of immature cells of 
undetennined lineage. 
Immunosuppression.. Continuous therapy: The recipients of the 
whole organs or cell suspensions (Table 1) were given intramuscular 
injections of 1.0 mglkwday tacrolimus (dissolved in HCO·60 and D 
mannitol; Fujisawa Pharmaceutical, Osaka, Japan) for 14 days 
starting on the day of transplantation, and weekly thereafter until 
100 days in animals surviving this long. 
Short-course therapy: For tolerance induction experiments, the 
same 2·week daily schedule of tacrolimus was begun in the BN rats 
on the day of the LEW organ or cell transplantation (day 0, Table 1), 
and supplemented with single injections on days 20 and 27. At 100 
days, 73 days after the last of the 16 doses, the surviving BN 
recipients were tested for donor-specific nonreactivity (tolerance) by 
challenging them in the sbsence of drug treatment with a LEW heart 
or liver or with a third· party (ACn heart. 
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FIGURE :2. Leukocyte profile of cell suspensions from LEW rat he-
matolymphopoietic organs and blood. Full data have been reported 
elsewhere (1Ol. The CD4 ~ and CaU~ phenotypes was characteristIC 
for thymocvtes. The monoclonal antibodies used for the CD4+ and 
CD8+ phenotypes were not linesge-specIfic but pnncipally Identified 
T cells. 
160 TRANSPLANTATION Vol. 60, No.2 
TABLE 1. Effect on survival and GVHD incidence of no, short course, and continuous treatment with tacrolimus following LEW-..,.BN 
organ and cell transplantion 
No treatment Short course tacrolimus" Continuous tacrolimusb 
Graft Median Median Median Survival (days) (days) Survival (days) (days) Survival (days) (days) 
Organe 
Heart 7,8,8, S, 8, 8, 10, 11 8.0 >100 (X9) >100 >100 (xs) >100 
Kidney 6,7,8,9 7.5 >100 (X4) >100 
Liver 23, 23, 23, 25, 28, 29, 28.5 >100 (x6) >100 >100 (X4) >100 
29, 30, 32, 27 
Small bowel 11,12,13 12.0 35,43,49 43.0 35, 42, 44, 47, 49, 54 45.5 
Cellsd 
Bone marrow >100 (X5) >100 >100 (X8) >100 >100 (X6) >100 
Lymph nodes >100 (X2) >100 43, 46, 46, 47, 47, 51, 47.0 36, 48, 50, 63, 71, 56.5 
53,54 >100 
Spleen >100 (X2) >100 51,53,53, 60, >100 60.0 62, 72, 74, 77, 78, 75.5 
(X 3) >100 
Thymus >100 (X8) >100 >100 (X3) >100 
Whole blood >100 (X3) >100 >100 (X8) >100 >100 (X3) >100 
a 1.0 mg/kglday for 14 days (days 0 to 13) and on days 20 and 27. 
b 1.0 mglkglday for 14 days (days 0 to 13), followed by weekly iIijection of 1.0 mglkg. 
C Animal (synonymous with graft) survival and occurrence of host GVHD (italics) after LEW -+ BN transplantation of different organs to 
untreated recipients (left) and to recipients given an abbreviated (middle) or continuous (right) COU1'8e of tacrolimus. 
d Animal survival and GVHD (italics) after Lv. infusion of different cell suspensions, using the same treatment as above. 
Erperimentai end points. Whole Organ graft survival: Liver, in-
testine, and kidney graft survival was considered synonymous with 
recipient death or sacrifice before then because of moribund state. 
Heterotopic heart graft survival ended with cessation of a palpable 
heartbeat, at which time the animals were sacrificed. 
GVHD and rejection: The rats were weighed at least twice a week, 
and observed for skin rashes, hair loss, diarrhea, and other clinical 
findings. All animals had histopathologic examination of tissues 
after death or sacrifice. Conventional criteria were used to diagnose 
GVHD and rejection. 
cells, and whole blood under a short COU1'8e of tacrolimus. The re-
sponse of lymphocytes from the primed animals was compared with 
that of naive BN lymphocytes, using irradiated naive LEW lympho-
cytes or appropriate third-party and syngeneic control cells as stim-
ulators (10). Operational tolerance was then determined directly by 
the survival after transplantation of LEW or ACI (third-party) 
hearts (groups 6, 8, 10, Table 2) or of LEW livers (group 14). 
Tolerance: The mixed lymphocyte response (MLR) was deter-
mined in BN rats 100 days after priming with bone marrow, thymus 
When priming had been done with LEW heart grafl;s, the recipi-
ents were challenged at 100 days with a second heart (group 3, Table 
2) or a liver (group 13). Recipients primed with livers were chal-
lenged with a heart (group 4). Experiments after priming with 
spleens were unsatisfactory (see Results). 
TABLE 2. LEW heart or liver survival in drug-free BN rats previously transplanted with different whole organs or leukocyte suspensions 
with or without an induction course oftacrolimus 
Organ/cell 
Pathology of challenge Chimerism 
Survival of challenge organ Median graft b Group pretreatment Tac:rolimus" n (daya) (daYI) (day 0) Cellular Obliterative 30 100 
infiltrate arteriopathy daya daya 
Heart as challenge organ (day 100) 
1 None 8 7, 8, 8, 8, 8, 8, 10, 11 B.O ++ +8 
2 None + 5 9,. 9, 9, 11, 13 9.0 ++ +S 
3 Heart + 6 > 100 (xS) >100 ++ +++ :: 
4 Liver + 3 >100 (X3) >100 ++ :: 
5 Bone marrow 3 4,5,6 5.0 ++ +8 
6 Bone marrow + 5 >100 (X5) >100 +1++ +1++ + :: 
7 Spleen + 2 14,71 42.5 NT" NT +++ NT 
8 Thymus + 6 6, 6, S, 7. 10. 13 6.5 +++ +S 
9 Blood 2 5, 6 5.5 ++ +8 NT NT 
10 Blood + 6 7, 8, 10. 13, 13. 15 11.5 +++ +S 
Liver as challenge organ (day 100l 
11 :-fone 10 23.23,23.25.28.29.29.30,32.37 28.5 ++ +8 
12 None + 3 20,24,31 24.0 ++ +S 
13 Heart + 2 > 100 (x2) >100 :: :: :: 
14 Bone marrow + 4 >100 (X4) >100 :!: + :!: 
a 1.0 mg/kg/day for 14 days on days 0 to 13. followed by two weekly injections on days 20 and 27. 
b (+8) = m.tlammatory artenus. 
, m. not tested. 
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In additional nonsurvival experiments used for histopathologic 
studies. BN animals primed under the same immunosuppression 
with LEW bone marrow were sacrificed 1,3,5, and 7 days (n=2 each) 
after transplantation of a challenge liver. The organ allografts and 
spleens were examined histopathologically for SlgnS of rejection and 
evidence of proliferation. respectively. 
Control experiments: The same protocols were followed in exper-
iments that omitted either the priming transplant procedure. the 
tacrolimus treatment, or both (Tables 1 and 2). Previously reported 
controls were not repeated, showing that priming with syngeneic 
bone marrow had no effect on either GVHD or the outcome of sub-
sequent transplantation (3), 
Pathologic studies. A complete autopsy was carried out on all 
rats. Tissues were fixed in formalin for paraffin embedding and 
routine H&E staining. Samples also were snap-frozen in liquid ni-
trogen for immunophenotypic analysis. Donor LEW cells were iden-
tified in BN recipients by using L-21-6, a monoclonal antibody that 
recognizes class II MHC antigens of most rat stains, except BN (3, 
10-12) (gift from Dr. Yuichi Iwaki, Professor of Pathology, Univer-
sity of Pittsburgh). The number of donor class II MHC positive cells 
present in recipients lymph nodes and spleen was estimated in a 
semiquantitative fashion according to the following scale: (-) donor 
cells (on whole-mount section of lymph node and spleen) not de-
tected; (:!:) rare, :55 cells; (+) occasional, 2:5 :510; (+ +) moderate, 
2: 10 :550; (+ + +) many donor cells 2:50. 
In conjunction with L-21-6, previously reported double-labeling 
immunofluorescence (4) and immunoperoxidase (12) techniques 
were used to determine the phenotype of surviving class II MHC-
positive donor cells. The reagent panel contained monoclonal anti-
bodies against all of the principal leukocyte subsets (panel available 
on request). 
Flow cytometric analysis: Donor and recipient hematolymphoid 
cells from recipient BN lymph nodes were examined after prepara-
tion of single-cell suspensions as described above and from recipient 
peripheral blood after lysis of red blood cells (red cell lysing buffer, 
Sigma. St. Louis, MOl. LEW or BN cells were identified with affinity-
purified biotinylated rat monoclonal antibodies (McAb) 163 and 42, 
(gifts from Dr. Heinz Kunz, Professor of Pathology, University of 
Pittsburgh) that react with MHC class I RTIAI and RTIAn antigens, 
respectively (J3l. Phycoerythrin-conjugated streptavidin (Pharmi-
gen, San Diego, CAl was used as a secondary antibody. Lineage 
phenotype was determined with the same panel of monoclonal anti-
bodies used for immunohistochemistry. Samples were analysed on 
an Epics flow cytometer (Coulter Corporation, Hialeah, FL). 
RESULTS 
Rejection. No treatment: Completion of organ rejection, 
defined as the day of animal death or sacrifice occurred at 
medians of 7.5, 8, 12. and 28.5 days after kidney, heart. 
intestine. and liver transplantation. respectively (Table 1, 
upper left). All of the organs had conventional histopatho-
logic findings of rejection. 
Infusion of the cell suspensions or blood caused no mortal-
ity (Table 1, bottom left). When the animals were spot-
checked at 30 days and sacrificed at 100 days, no donor cells 
could be found in any recipient tissues. These were assumed 
to have been rejected. 
Short-course and contmuous tacrolimus: With either regi-
men of immunosuppressIOn. all liver and heart recipients 
and their grafts survived 100 days (Table 1. upper middle 
and right). The livers were essentlally normal using both 
treatment regimens. However, the hearts treated with the 
short course had developed obliterative artenopathy WIth 
lymphyocyhc infiltrates 73 days after drug distomnuance: 
these abnormalities were not present under continuous ther-
apy. Contmuously treated kldnev recipients also had essen-
bally normal allografts at the end of 100 days. All intestinal 
recipients died at about 6 weeks postoperatively whether 
given a short or continuous course of immunosuppression 
(Table I, upper middle and right). Histopathologic stigmas of 
rejection were either not present or minimal. 
Rejection of cell suspensions or blood leukocytes could not 
be monitored decisively. However, avoidance of rejection of 
lymph node leukocytes and splenocytes at 30 days and time 
of death under both regimens of immunosuppression was 
evidenced by the copious presence of these donor cells in the 
tissues of all animals; 22 of these 27 rats died before 100 days 
(Table 1, bottom middle and right). After bone marrow infu-
sion, donor cells also could invariably be found, but in con-
trast none of these animals died (survival 14/14). Infusion of 
thymus suspensions and whole blood under immunosuppres-
sion also was without mortality (Table 1, bottom middle and 
right). However, donor leukocytes could never be found in the 
tissues, implying their rejection or failed initial engraftment. 
The differences in outcome with the suspensions of lymph 
node. spleen. bone marrow, and thymus cells could not be 
explained by different cell doses (2.5 X 108 in all). 
GVHD. NO' treatment: Intestinal recipients developed 
transient skin rashes as previously reported (l0, 14, 15) that 
quickly receded as the bowel and presumably the donor leu-
kocytes were rejected. No evidence of GVHD Was detected 
with any of the other organs (Table 1, upper left) or with the 
cell suspensions (lower left). 
Short-course and continuous tacrolimus: Similar to previ-
ous report with the LEW - BN strain combination (10, 14, 
15), intestinal recipients developed clinically obvious and 
histopahtologically confirmed GVHD that was equally lethal 
whether immunosuppression was stopped after 27 days 
(n=3) or continued (n=6) (Table 1, upper middle and right), 
Liver recipients were healthy with both treatment regimens, 
including absence of clinical GVHD despite the presence in' 
some animals of a mononuclear celltT cell-rich infiltrate of 
donor cells in the epidermis. Kidney and heart recipients 
(Table 1, top middle and right) were clinically and his-
topathologically free of GVHD. 
Rats given thymus ceU suspensions and whole blood never 
developed GVHD, which was explained by the absence of 
donor cells in the tissues of these animals. Bone marrow 
suspensions, however. resulted in obvious donor cell engraft-
ment under both treatment schedules. The animals were 
ostensibly healthy despite the presence of dendritic-shaped 
donor cells in the dermis (without epidermal infiltration) that 
were most evident in animals treated continuously for 100 
days. The same dose of splenocytes and lymph node leuko-
cytes always caused GVHD, and this was the cause of the 
usual fatal outcome (Table 1. bottom middle and right). 
Correlation with chimerism after short-course tacrolimus: 
GVHD was associated with the density of chrimerism as well 
as its T cell constituency tTables 3 and 4). Thirty days after 
the primary allotransplantations and 3 days after discon-
tinuance of tacrolimus, striking chimerism was detected im-
munocytochemically with the L-21-6 (class rr) antibody in 
the tissues of recipients of small bowel, spienocytes. and 
lymph node leukocytes. Double-labeling showed that these 
Included T cells (alpha-beta qCo~lI B cells (IgM+), dendritic 
cells rOX62+), macrophages (ED2+l, and natural killer cells 
I ~h 3.2.3 + 1. Flow cytametry of penpheral blood or reclplent 
·;1 
1 
I 
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TABLE 3. Chimerism in BN recipients 30 and 100 days after transplantation of LEW organs or leukocyte suspensions under a short 
course of tacrolimus" 
30 Days 
Flow Immunohistochemistry cytometry 
(class Db (class mc 
Small bowel 4.0:!:2.3%d +++ 
Lymph nodes 4. I:!: 1.8% +++ 
Spleen 7.5:!:0.2% +++ 
Liver <1.0% ++ 
Bone marrow 0 + 
Heart 0 :!: 
Kidney NT :!: 
Thymus NT 
Blood NT 
a 1.0 mglkglday on days 0 to 13; 20, and 27. 
b McAb 163. blood samples, or recipient lymph node suspensions. 
c L-21-6Ab, spleen. and cervical lymph nodes. 
Ii Mean:!: SO . 
• NT: not tested; M: multilineage; T: T lymphocyte. 
f Delayed acute rejection. 
II Chronic rejection. 
100 Days 
Lineage Immunocytochemistry Tolerance GVHD (class Ill" 
T> M' No 100% 
T>M No 100% 
T>M Minimal' 100% 
M=T :!: Yes 0 
M>T :!: Yes 0 
Partial8 0 
NT 0 
No 0 
No 0 
TABLE 4. Location and number of L·21-6-positive cells in different tissues of recipient 30 days after small intestine, liver, and 
bone marrow transplantation 
Tissue 
Donor cells after transplantation number" !location 
Small intestine 
Spleen + Red pulp, PALse 
Thymus -1+ Distorted architecture, small 
medulla 
Lymph nodes +++ Cortical, T cell-rich 
Skin +++ Dermal-epidermal junction 
Liver 
a Donor cells on whole-mount section. 
b (-1+) rare; (+) 5< <10; (++) 10< <50; (+++) >50. 
c PALS, periarteriolar lymphoid shealth. 
lymph node suspensions using anti LEW MHC class I anti-
body (McAb 163) showed that 4-7.5% of the cells were donor 
(Table 3). In the small bowel recipients, more than 60% were 
T cells (alpha-beta TCR") of the W 3/25+ subset, but donor B 
cells (OX33+) could also be detected. 
In bone marrow and liver recipients, none of which devel-
oped GVHD, too few donor cells were present at 30 days to 
permit flow cytometry. However, immunochemical labeling 
with the L-21-6 class II antibody and double-labeling with 
lineage phenotype markers permitted quantitative and qual-
itative estimates of the chimerism (Tables 3 and 4). The 
spleen and cervical lymph nodes from liver recipients con-
tained 10-50 donor cells per whole mount section, with a 
clear dominance of T cells. All lineages also were present in 
the tissues of the less densely chimeric bone marrow recipi-
ents (5-10 cells/whole-mount section), but without a domi-
nant lineage. The donor cells in kidney and heart recipients 
were too rare to permit lineage analysis. No donor cells could 
be found after 30 days in animals conditioned with thymus 
cell suspensions or whole blood. 
At 100 days after primary allotransplantation. 73 days 
after the last drug dose. donor class II (L·21·6 -) cells had 
become sparse m the liver and bone marrow recipients (estl-
Liver Bone marrow 
+ PALS, red pulp + PALS 
+ Medulla ++ Medulla 
++ Mixed cortical and + Paracortical, dendritic 
paracortical cell-rich 
-1+ Deep dermis -1+ Deep dermis 
NA + Portal tracts, rare 
sinusoids 
mated <0.01%). However, T, B, and dendritic cell lineages 
still could be detected. No definite L-21-6'" cells were found in 
the kidney and heart recipients by the cytostaining tech-
niques. Recipients of thymus cells and whole blood were 
negative for chimerism (Table 3). 
Tolerance induction. Organ-induced: Although lethal 
GVHD after small bowel transplantation precluded the dem-
onstration of tolerance by transplantation of a challenge do-
nor organ, none of the priming allografts had evidence of 
rejection at the time of death, 8 to 22 days after discontinu-
ance of immunosuppression, suggesting self tolerance had 
been induced by the intestine. 
In BN recipients primed with LEW heart (n = 6) and liver 
(n=3) grafts under the short course of tacrolimus, tolerance 
to challenge LEW hearts was convincingly demonstrated. All 
of the challenge hearts transplanted at 100 days survived for 
> 100 additional days (groups 3 and 4. Table 2), compared 
with the median survival of 8 days in naive control recipients 
(group 1, Table 21. The hearts preceded by livers appeared to 
beat more vigorously than those preceded by hearts, an im· 
pression of superiority that was confinned by histopatholOgiC 
study (see below I. ACI challenge hearts (third-party controls) 
at 100 days were nonnally rejected. 
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Conversely, a priming heart was tolerogenic for a subse-
quently transplanted liver (group 13. Table 2). 
Lymphopoietic cell-induced: Thymus cell suspensions 
(group 8) and whole blood (group 10) under short-course 
tacrolimus . were not tolerogenic for hearts. and actually re-
duced survival to below the 8 days recorded in naive LEW ~ 
BN control experiments. Only 2 experiments could be at-
tempted at 100 days in splenocyte primed animals. Both rats 
had slowly resolving GVHD after discontinuance of tacroli-
mus at 27 days. Survival of the 2 challenge LEW heart 
allografts were prolonged to 14 and 71 days before the organs 
were rejected (group 7, Table 2). 
In contrast, LEW bone marrow cell suspensions infused 
under the same treatment conditions allowed > lOO-day sur-
vival of all LEW challenge hearts (group 6, Table 2) and 
livers (group 14). The effect was donor-specific in that 3 of 3 
BN rats primed with LEW bone marrow rejected third-party 
ACI hearts in 6 days. 
The loss of antidonor alloreactivity in the intact animals 
was not reflected in the MLR results. Lymphocytes from the 
tolerant BN rats responded equivalently to naive LEW and 
ACI stimulator cells. This pattern of response was essentially 
the same as that of lymphocytes obtained from naive BN rats 
from nontolerant BN rats reconditioned with thymus cells or 
blood transfusion who rejected their heart grafts in the usual 
time (Table 5). 
Alloreactivity was also demonstrated in the operationally 
tolerant bone marrow primed animals challenged with liver 
allografts at 100 days and sacrificed for histopathologic stud-
ies 1-7 days later. Between 3 and 7 days posttransplantation 
a vigorous but spontaneously resolving alloresponse was re-
flected in the LEW liver allografts by a transient heavy 
mononuclear infiltration that coincided with obvious prolif-
eration in the host spleen. 
Correlation with chimerism: Tolerance to challenge organs 
was not accomplished in any cohort in which chimerism was 
not demonstrable 30 days after the priming allotransplanta-
tion. In spite of the poor chimerism produced by priming 
hearts. all of the livers were accepted at 100 days and were 
normal 100 days later. Challenge livers were of equally good 
quality after transplantation to the recipients primed with 
bone marrow who had better and more persistent chimerism. 
The perfection of these results precluded a distinction be-
tween cardiac and hepatic tolerogenicity, when the liver was 
used as the challenge organ. 
TABLE 5. MLR against BN (syngeneic I. LEW (donor I. and ACI 
(third-party I In naive and bone marrow-. whole blood-. or 
thymocyte-primed BN rats~ 
Stimulator 
BN responder' BN LEW ACI 
I svngeneici (donorl I third· party I 
:--faive 235::78 36.558:: 1844 26.979::6276 
Bone marrow 703:: 184 21.122::5176 :24.450:::: 12.367 
Blood 965::449 ~MK9UP::RO1R 36.020::7877 
Thymus 911::55 15.651:: 4454 17.842::4181 
" ."-11 values are mean:: SD (cpm) of tnplicate wells. 
I, BN ammals received bone marrow, thmocvtes (250x lOti) or 3 ml 
whole blood from LEW (dav 01 and were treated Wlth tacrolimus 11.0 
rnlZlkll/dav on days () to 13 and 20, and 27). Cel'Vlcaj Ivmph nodes 
"ere obtamed on day 100 for ;lnajYSls. 
In contrast. the heart as a challenge organ provided a 
discriminating test of tolerogenicity. Although all of the 
hearts transplanted to liver. bone marrow, and heart-primed 
recipients beat for the lOO-day period of subsequent obser-
va.tion. the rank order of tolerogenicity was readily deter-
mined by histopathologic grading. The priming liver gave the 
best protection. bone marrow next, and the heart least CTable 
2l. These scores paralleled the density of chimerism CTable 
.3). Cardiac allografts in liver-primed recipients were essen-
tially normal. whereas those in the heart-primed cohort had 
advanced findings of chronic rejection (Fig. 3) including oblit-
erative arteriopathy and multiple subendocardial, perivascu-
lar, and interstitial lymphocytic infiltrates similar to the 
"QUilty" lesions seen in human cardiac allografts (16). The 
challenge hearts in bone marrow primed recipients had a 
mild and patchy version of these lesions. 
Control experiments: Omission of either the short course of 
immunosuppression (Table 2, groups 5, 9) or the allograft 
(groups 2. 12) from the primary stage of the experiment 
FIGURE J. Chrome rejection In LEW challenge heart 100 days after 
transplantatIOn to a tolerant reCIpient that had been pnmed with 
another LEW heart 100 days before transplantation. The reCIpIent 
was treated With a short course of tacrolimus after the pnmmg 
transplantation. and had been dru~-free for 73 days at the tIme of 
challen'l'e engTaftment. I A) Cross-sectIOn of challen~e heart allograft 
,It saenfice. Arrows = subendocardiallvrnphocyte a~gregates I Quilty 
leSIOns!. I H&E stam, onlnnal magmficntlon approxlmatelv .\ '20.) (B) 
I)cc!uslve artenai leSIOns ot' chrome relectlon. Note mInimal cellular 
Inriltrate. I H&E ;tatn. ungmai mal;mlicutlon approXImately, :':00.) 
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eliminated the tolerogenic effect at the time of the challenge 
transplantation. Preliminary infusion of priming bone mar-
row cells or whole blood without tacrolimus appeared to 
cause more rapid rejection of the subsequent heart allografts 
(groups 5, 9, Table 2). 
DISCUSSION 
Interest in the infusion of donor antigen or live cells to 
facilitate acceptance of organ allografts originated with the 
demonstration by Billingham, Brent, and Medawar (17, 18) 
that chimerism and acquired tolerance (proved with skin 
transplantation) could be produced by infusion of adult 
mouse splenocytes into immunologically immature (defense-
less) recipients during gestation or neonatally. After Billing-
ham and Brent (19) and, independently, Simonsen (20) 
showed that the engrafted splenocytes posed a risk of GVHD, 
Billingham and Brent (21) reported that cell suspensions of 
all the central lymphoid organs had the same range of tolero-
genicity except for the weakly effective thymocytes. However, 
of the potent tolerogens (bone marrow, spleen, lymph node 
cells, and buffy coat), bone marrow was the least likely to 
cause GVHD in strain combinations predisposed to this com-
plication (21). Main and Prehn (22) successfully simulated 
the neonatal tolerance in adult mice, using supralethal irra-
diation followed by reconstitution with donor bone marrow. 
This prototype strategy was used for the first successful 
clinical bone marrow transplantations in 1968 (23-25) and 
was governed, as in the rodent models, by the need for good 
histocompatibility matching to avoid lethal GVHD. 
The extension of this strategy to prepare patients for organ 
allografts seemed obvious (26), as summarized by Rapaport 
et al. (27). However, the momentum carrying organ and bone 
marrow transplantation on a common pathway was lost be-
tween 1959 and 1962 when the combination of total-body 
irradiation and bone marrow replacement proved to be uni-
formly lethal as a step to organ transplantation in large 
outbred animals (28, 29). More important, the incentive to 
continue such efforts was eroded when 6 human kidney al-
lografts, one in Boston (30) and 5 in Paris (31,32), functioned 
for extended periods (> 1 year) after their transplantation 
between January 1959 and early 1962 following sublethal 
total-body irradiation without bone marrow. The case for a 
bone marrow component declined further when extended 
canine (33) and human (34, 35) kidney transplant survival 
was accomplished solely with drugs. Further human experi-
ence was particularly influential because the successes using 
combined azathioprine-prednisone therapy (36) exceeded 
manyfold what had been accomplished in dogs. The clonal 
deletion hypothesis that had been accepted as the basis of the 
classic tolerance models did not provide a tenable explana-
tion for the success of whole organ transplantation (37-43). 
In the rodent irradiation chimera preparations and with 
clinical bone marrow transplantation, the primary objective 
of cytoablation was immunosuppression. Eventually the be-
lief took root (discussed recently [44, 45]) that an additional 
critically important effect of cytoablation or cytoreduction 
was to "make space" in the recipient microenvironment for 
the infused donor cells. However, this assumption was not 
supported by some of the earliest therapeutically relevant 
eJqleriments shoWlng that neither ~space" nor even immuno-
suppressIOn was required in adult mice for production of 
chlmensm and tolerance under specific cm:umstances that 
were largely determined by histocompatibility variables. In 
1959, Mariani, Martinez, Smith, and Good (46) reported that 
adult splenocytes could induce chimerism and tolerance to 
skin grafts across the sex-linked Eichwald-Silmser histocom-
patibility difference in immunologically competent mature 
unconditioned syngeneic mice. Brent and Gowland (47) de-
scribed the same thing in selected allogeneic mouse strain 
combinations, using frequent inoculations of very large num-
bers of cells. 
In addition, Martinez, Shapiro, and Good (48) demon-
strated reciprocal tolerance induction of members of mixed 
circulatory parabiotic mouse pairs-more or less easily when 
the joined animals had weak and strong histocompatibility 
differences, respectively. The parabiotic animals were mixed 
chimeras, mimicking the effects of placental cross-circulation 
described by Owen in freemartin cattle (49), that included 
the acceptance of reciprocal skin grafts (50). The findings of 
Martinez, Shapiro, and Good (48) defined a principle that 
presaged the GVHD resistance of mixed chimerism in the 
total-lymphoid irradiation models of Slavin and Strober (51, 
52) and the experiments ofTIdstad and Sachs (53-56). A more 
recent analogy to the archival parabiotic experiments has 
been provided by the mouse orthotopic hepatic transplant 
model of Qian et al. (4) in which the liver allograft, which is 
spontaneously accepted with most strain combinations, has 
had the uncanny resemblance of a tolerogenic parabiotic 
partner to its chimeric and reciprocally tolerogenic recipient. 
Although leukocyte chimerism seemingly had been proved 
by 1960 to be unnecessary for whole organ transplantation, 
the adjuvant use of white cells was never far from the con-
sciousness of transplant surgeons. In a 1964 text, based on a 
series of successful renal transplantations, attention was 
drawn to" ... current research in many laboratories which is 
directed toward achieving enhancement by inoculating the 
recipient with [donor] spleen, liver, or peripheral white cells" 
(38). The unifying idea that donor leukocytes within tissue 
grafts could do the same thing was advanced as early as 1970 
by Monaco and Wood who wrote: "Various organs may con-
tain variable numbers of mobilizable lymphoid cells which 
may constitute a significant antigenic innoculum. It is pos-
sible that treatment with ALS may facilitate induction of 
tolerance by the contained lymphoid cells, thus permitting 
the withdrawal of ALS without the onset of rejection" (57). 
The literature of the last 30 years describing attempts to 
induce tolerance in organ recipients-using live or dead cells 
of all kinds and antigen extracts-is too vast and confusing to 
discuss here. However, the independent lines of inquiry by 
Monaco and CaIne into the meaning of organ transplant 
tolerance deserve specific comment because they are directly 
relevant to our studies of low-level chimerism reported 
herein and elsewhere. While only suspecting that infused 
donor bone marrow leukocytes could suvive in small numbers 
for long periods and serve as the "veto cells" (58-60) the 
toierogenicity of which had been defined by Miller \61-63), 
Monaco, Wood, and their colleagues have contended since 
1966 that tissue and organ recipients could benefit from the 
antigen load of adjuvant live donor leukocytes. In most of 
their animal experiments, cryopreserved cells were glven a 
few days to 3 weeks after the primary allograft, under im-
munosuppression with ALS or ALG during the intervemng 
interval. Tolerance was demonstrated imtially with skin 
grafting m mouse F 1 oiTspnng - parent expenments that 
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precluded a GVHD risk (64) and then in non-F 1 models (57, 
65-67). After testing the bone marrow-ALS strategy for kid-
ney transplantation in dogs (67, 68), they extended it to a 
human cadaveric renal case (69) under conventional cocktail 
immunosuppression (including ALG) that defined what has 
been called the Monaco model. 
In subhuman primate variations on the Monaco bone mar-
row model, Thomas et al. were able to produce tolerance to 
kidney allografts (70), observed nests of donor leukocytes on 
the surface of the transplanted kidneys (71), and found evi-
dence of veto cells (72) similar to those seen by Maki in mice 
(58, 59). Extensive formal trials in renal (73-75) and liver 
transplantation (76) were recently reported from the Univer-
sity of Alabama and England, respectively. No adverse ef-
fects were attributable to the bone marrow, and in the renal 
trials there may have been a clinical benefit. Barber et al. 
(74) detected evidence of donor DNA in the blood of some of 
their nonmarrow control recipients with polymerase chain 
reaction (PCR) probes, a finding suspected at the time to be 
an artefact. 
The significance of this recently summarized massive body 
of work (77), most of it using bone marrow for the innoculum, 
could not be fully appreciated until 1992 when it was discov-
ered that the bone marrow-derived "passenger leukocytes," 
that are an important component of all organs, migrated 
after human organ transplantation and survived ubiqui-
tously in recipient tissues for years or decades (1,2, 78-80). 
With the new information, it was realized that, except for its 
delayed timing, the strategy of the "Monaco models" was an 
iatrogenic amplification of a natural posttransplant event, 
culminating in microchimerism. In addition, the linkage was 
evident between organ allograft acceptance, the tolerance of 
clinical bone marrow transplantation, and the originally de-
scribed acquired tolerance of Billingham, Brent, and Me-
dawar. All were variations of the same principle. 
We have proposed that the interaction, each with the 
other, of the 2 coexisting cell popUlations after either isolated 
or leukocyte-augmented organ transplantation is the funda-
mental explanation of organ allograft acceptance and of 
transplantation tolerance generally (1-5, 78-82). A similar 
reciprocal reaction hypothesis to explain acquired tolerance 
after splenocyte and bone malTOW transplantation was ad-
vanced by Simonsen 35 years ago (83, 84) and supported by 
Michie, Zeiss, and Woodruff (85). The idea faded when it 
could not be proved. However, the rapidity of its abandon-
ment may have reflected opposition to the implication that 
transplantation tolerance was an active process, not the thy-
mic clonal deletion that had become the hardening concensus 
explanation in the early 1960s for transplantation tolerance. 
In addition, the substrate for a two-way immune interaction 
in the context of organ (as opposed to bone marrow or spleno-
cyte) transplantation was not recognized to be present until 
the discovery of spontaneous chimerism 30 years later. 
The fully allogeneic LEW -.. BN rat strain combination 
used in the experiments reported here had unusual advan-
tages for examination of the HVG and graft-versus-host 
(GVH) components of the ~O-way paradigm" and of the effect 
of expanding the GVH limb. First. the distinction of donor 
from recipient leukocytes in tissues and blood could be made 
with preclsion because ofthe aV8.1lability ofthe L-21-6 mono-
clonal antibody that densely stains class II+ cells of almost 
all rat strains. including LEW, but not those from BN rats \3, 
10-12). In addition, the BN rat is highly susceptible to 
GVHD (10, 15), allowing this usually "invisible" limb of the 
two-way immune reaction to be readily exposed for investi-
gation. Finally, the HVG (rejection) limb in both strain di-
rections is weak enough to allow the induction of tolerance to 
at least one kind of whole organ allograft of each strain after 
transplantation to recipients of the other strain, using either 
a short course of induction immunosuppression (3, 11, 86, 87) 
or, in the case ofBN -+ LEW liver replacement, no treatment 
at all (7, 88). 
The outcome of the LEW-BN experiments herein reported 
provided strong support for the two-way paradigm (82) as 
well as general guidelines for its therapeutic exploitation. 
The first question asked was one of safety. As previously 
reported in the LEW -+ BN recipient (10, 14, 15), the risk of 
clinical GVHD from intestinal transplantation under either 
an abbreviated or continuous course of tacrolimus was over-
whelming, similar to that in the parent -. offspring F 1 hybrid 
(defenseless recipient) experiments of Monchik and Russell 
(89). In contrast, GVHD was never seen after liver, kidney, or 
heart transplantation. Cell suspensions of splenocytes and 
lymph node leukocytes behaved like the intestine, invariably 
causing GVHD that was usually fatal, while the same dose of 
easily engrafted bone marrow never did. Thymus leukocytes 
and the much smaller doses of blood leukocytes did not en-
graft. 
The discontinuance of immunosuppression after 4 weeks in 
the recipients of intestine, or in animals given lymph node 
and spleen suspensions, did not ameliorate the lethal course 
of the GVHD, which was highly associated with the florid 
persistence of donor leukocytes in the recipient tissues. Un-
der the same treatment conditions, the donor cells dwindled 
but were still easily detectable at 100 days in the liver and 
bone marrow recipients. The chimeric cells could no longer be 
detected at 100 days in animals given hearts. These obser-
vations confirmed those in earlier reported experiments in 
which liver transplant-induced chimerism was documented 
out to 300 days (3), whereas the chimerism induced by hearts 
had already reached a very low but still detectable level by 
the end of the first 30 postoperative days (90). More sensitive 
probes were not available to determine trace chimerism in 
the heart recipients of the present report at the time of 
challenge transplantation at 100 days. 
Toierogenicity of the various cell and organ grafts could not 
be conclusively determined in the presence of clinical GVHD. 
However, the liver, bone marrow, and heart defined in that 
order of completeness a spectrum of ultimately drug-free self 
tolerance, as well as tolerance to subsequently transplanted 
donor strain organs. The tolerance was strongly associated 
with tissue microchimerism. which was poorest after priming 
with hearts. Although the cardiac allografts were unques-
tionably toierogenic. the development in them of chronic re-
jection after drug discontinuance and the same findings in 
the subsequent challenge hearts showed how incomplete the 
tolerance was. However, even this suboptimal immunologic 
status allowed not only acceptance but long-term rejection-
free maintenance of challenge livers. presumably because of 
the heavy boost of donor-strain leukocytes brought in by the 
test liver. This assumption has support from elegant mouse 
experiments by Smith et al. (91) in which the allograit com-
binatlOn was bone marrow and skin. The resulting chimer-
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ism in the mouse skin grafts originated from both donor 
sources. 
The liver, bone marrow, and heart were tolerogenic in that 
order of potency under the circumstances of our experiments, 
but the inability to quantitate the leukocyte dose of whole 
organ grafts precluded sweeping conclusions about the role of 
either dose or quality of the passenger leukocyte lineages. 
Because Kupffer cells alone are 15-20% as numerous as 
hepatocytes in the liver and contribute about 2.5% of the 
liver's cellular protein (compared with 15% by the hepato-
cytes) (92), the load of white cells contained in a 5 g liver used 
for a 250 g recipient would be huge (an estimated 100 mg) 
compared with that in a cardiac allograft, and substantially 
more by weight than that used in the bone marrow experi-
ments. 
When the dose factor was controlled, as was possible in a 
comparison among the 4 cell suspensions, the results 
strongly supported the long-held contention of Wood and 
Monaco (57, 67, 93) that bone marrow would be a potently 
tolerogenic cell suspension for clinical tolerance induction in 
whole organ recipients. The present experiments also showed 
that the bone marrow is the most free of GVHD, being in-
comparably safer than spleen or lymph node cells. Acquisi-
tion of this kind of information depends upon testing in 
GVHD-prone models like the one used for our experiments. A 
GVHD/tolerogenicity spectrum of different cell sources very 
similar to that in our rat studies was observed 35 years ago 
by Billingham and Brent (21) using several mouse strain 
combinations in their neonatal tolerance model. By implica-
tion, the striking differences in the GVHD/tolerance outcome 
with the various leukocyte suspensions was a function of 
their lineage profile. The numerous immature cells of unde-
termined lineage in LEW bone marrow (Fig. 2) resembled 
those studied by Lu et al. (94) in the mouse liver, and shown 
by them to include precursor dendritic cells that we (1-5,95, 
96) and others (97) have postulated to present donor antigen 
in a tolerogenic context, and to be critical for peripheral 
engraftment and persistence of tolerance maintaining micro-
chimeric populations. Lu and Thomson et al. have shown 
that such cells are exported from the transplanted liver and 
establish ubiquitous cellular oases consisting of precursor 
(and presumably stem) cells of mixed donor and recipient 
phenotype (98, 99). Such observations as well as the results 
of the present study have reduced the distinction of bone 
marrow versus liver leukocyte source to a largely semantic 
one. 
In chimeric recipient tissues, over-representation of donor 
T lymphocytes was associated with the undesirable result of 
GVHD. However, because the benign chimerism following 
the highly tolerogenic liver and bone marrow allotransplan-
tations also had a generous T cell component, we suspect that 
the engraftment as well as the tolerogenic processes are 
complex, beyond the independent capability of any single 
lineage. The ineffectiveness of blood was undoubtedly due to 
the small dose of leukocytes infused (estimated 2.5-3 x 107 ), 
which was only VIO that of the cell suspensions. The impor-
tance of doseage with all of the cell suspenSiOns was demon-
strated by Billingham and Silvers (JOO) who confirmed Bill-
ingham and Brent'S (18) original obsenrations that blood 
leukocytes in sufficient quantity are easily engrafted, and 
can be tal erogenic or cause GVHD. The same thing Wlth 
highly punfied blood leukocytes was emphasized by DeFazio 
et a1. (101), who also showed the ability of these cells to 
sensitize (102) as noted in our nonimmunosuppressed rats. 
However, the perplexing inability to transplant thymus cell 
suspensions suggested that even the initial step of engraft-
ment is dependent on an appropriate multiline age mix from 
which some essential ingredient was missing in the T cell-
dominated thymic leukocyte suspension. The difficulty of 
engrafting adult thymocytes was first described in mice (21, 
100), but not with all strain combinations (103), 
Beyond its relevance to Monaco's research, the two-way 
paradigm allows reexamination of the literature on the in-
herent tolerogenicity of whole organs, much of which can be 
traced back to the 1969 report by Calne et al. (104). It was 
already well known by then that canine liver allografts could 
self-induce tolerance during a 4-month postoperative course 
of azathioprine (105), and that this occurred even more fre-
quently in untreated outbred pigs (106-110), many of which 
passed through spontaneously resolving rejection crises (109, 
111,112). First in pigs (104) and then in rodents (88, 113, 
114), Calne, Zimmermann, and Kamada-and subsequently 
others (115, 116}-showed that the tolerization extended to 
other donor organs transplanted at the same time or later. 
Caine's hypothesis that soluble MHC class I antigen secreted 
by the hepatocytes was responsible (104, 113, 117-120) was 
weakened when Corry et aI. (121) and Russell et aI. (122) 
showed that mouse heart and kidney allografts were also 
tolerogenic, but with weaker MHC disparities. The results 
reported herein leave little doubt that organ tolerogenicity is 
not liver-specific, but rather an extreme example of a phe-
nomenon based on donor leukocyte chimerism that is com-
mon to all tissues and organs. 
How the miniscule population (including stem cells) of 
chimeric donor leukocytes is able to be integrated and sur-
vive within the dominant recipient immune system has not 
been resolved despite detailed study (4, 94-96, 98, 99, 123-
126). In 1992, Calne (127) raised the possibility that a "spe-
cial type of self-limiting Kupffer cell graft versus host reac· 
tion causes T cell decloning of the recipient" and asked "could 
a similar effect be produced with isolated Kupffer cells or 
other phagocytes? To be active, must they reside in live 
sinusoids, or could they perfonn as well elsewhere?" In an 
additional modification of the original Cambridge hypothesis 
that further accommodated the recent chimerism discoveries, 
but still in the context of a liver-specific phenomenon (128, 
129), Calne et al. have continued to assign a role to soluble 
hepatocyte-secreted class I antigen as a critical cofactor with-
out which engraftmentand persistence of the donor leuko-
cytes cannot occur. There has been little direct experimental 
support for this position in whole animals. Although an im· 
munosuppressive effect of serum was ascribed by Kamada et 
al. (113) to soluble class I antigens, purified antigens in 
subsequent studies have had minimal (119) or no immuno-
suppressive or tolerogenic action (] 30, 131). Finally, results 
from studies in mice (4) including those with "knocked-out" 
class I genes (132) have further eroded the hypothesis. Nev-
ertheless. a role of soluble class I antigens in tolerance cannot 
easily be dismissed, largely because of results from in vitro 
studies (133) suggesting the modulation by soluble antigen of 
cell· mediated cytotoxicity. 
In SPIte of these reservations, Calne's ideas remain collec· 
tlvely powerful as well as relevant to all organ allografts if 
f.,'Towth factors rather than soluble class I antigens are envi-
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sioned to be facilitators of chimerism. This concept could 
explain many enigmatic observations, such as the greater 
ease noted by Liegeois et al. (134) of engrafting bone marrow 
in mice in conjunction vvith donor skin compared with bone 
marrow alone, a collaboration termed by them «reciprocal 
graft enhancement. n Takahashi et al. (59) have shown an 
increased tolerogenicity of bone marrow that was cultured 
vvith IL-2 and IL-3 prior to administration. Many growth 
factors are cytokines, including most of those discovered 
during research on liver regeneration (35). Although the 
greatest sources of growth factors are leukocytes of various 
lineages (136-138), granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) and granulocyte colony-stimulating 
factor (G-CSF) are only two examples of diverse-action can-
didates known to be secreted by hepatocytes (139, 140) as 
well as by parenchymal cells of other organs. 
Growth factor therapy is beyond the pilot phase in the bone 
marrow transplant field for the promotion of alloengraftment 
(141). Further efforts vvill be facilitated by the rapidly ex-
panding discovery and availability of recombinant growth 
factors, most of which have multiple physiologic actions 
(135). With recognition of the common basis for bone marrow 
transplantation and organ acceptance (chimerism), therapy 
with these molecules could become an adjunct to, or even a 
substitute for, the leukocyte augmentation in whole organ 
recipients currently under trial (142). For example, we sus-
pect that increased chimerism explains the significant im-
provement in BN ...... LEW heart allograft survival described 
by Foster et al. in animals treated postoperatively with G-
CSF (143). Conversely, Monaco et al. (144) have described 
improved tolerance induction using donor bone marrow pre-
treated vvith GM-CSF. 
The foreoging discussion concerns central issues of chimer-
ism augmentation in clinical tolerance induction trials such 
as we are conducting (142). However, we have frequently 
emphasized (1,2,5,82,142) that chimerism is in no sense a 
substitute for the immunosuppression upon which the donor 
leukocyte engraftment and the eventual stability of chimer-
ism depends-especially if the MHC barrier is a difficult one 
or if the chimeric population is small. In humans, the divi-
dend of stable chimerism and its corollary of drug-free toler-
ance are expected to take years rather than the days or weeks 
of our rodent experiments. The operationally tolerant state 
can not be identified by current tests, including cell-mediated 
lymphocytotoxicity (CML), any more accurately in humans 
(80) than in rodents (4, 125). The MLR was always intact in 
our bone marrow-conditioned rat recipients of the present 
study, which accepted heart and liver allografts in every 
experiment. 
Previous investigators have used the term "split tolerance" 
to describe the dichotomy between the in vitro and in vivo 
results (J25, 145). The subtle changes in the in vivo immu-
nologic repertoire of our bone marrow-primed rat recipients 
that pennitted challenge hearts to survive did not prevent 
histopathologically verified chronic rejection of the cardiac 
grafts. However, the rejection of livers was self-resolving, as 
has been observed many times before Wlth a variety of organs 
in small and large animals with and without induction im-
munosuppression-exemplified by the original pig liver 
studies (]04. 109, 111. 112) and most completely in studies of 
the exceptIonally valuable mouse liver transplantation model 
1.4l. These events are compatIble Wlth the v:iew that the 
tolerance induction is an inherently active rather than dele-
. tional process (3, 5, 58-60, 81, 82). 
Finally, the characteristic dwindling of the chimeric cell 
population following whole organ or leukocyte transplanta-
tion deserves special comment. This was accurately de-
scribed by Liegeois (a former fellow of Monaco), Charriere, 
and Brennan (146) after bone marrow infusion in mice-to a 
low level after 5 months, for which they coined the term 
"microchimerism." The association of loss of tolerance and 
chronic rejection vvith further decline of these cells could be 
prevented completely in our rat heart recipients, by contin-
uation of tacrolimus. Presumably this was not accomplished 
merely by retention of an inadequate number of residual 
chimeric cells, but also by allovving new ones to be generated. 
The process of peripheral donor leukocyte cell renewal dem-
onstrated by Lu and Thomson et al. (98,99) is the postulated 
mechanism. No matter what means of tolerance induction is 
used, or the level of resulting chimerism, the hazard of pre-
mature discontinuance of therapy in clinical practice is self-
evident. 
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IN VIVO REACTIVITY OF T CELL CLONES ISOLATED FROM 
MICE WITH SYNGENEIC GRAFT-VERSUS-HOST DISEASE! 
J. Scon BRYSON,2,5 HELENE LAKE-BULLOCK, 3 DAVID L. PFLUGH, C. DARRELL JENNINGS, 
P. MICHAEL STUART," BETl'Y E. CAYWOOD, AND ALAN M. KAPLAN 
Departments of Internal Medicine, Microbiology, and Immunology and Pathology, Chandler Medical Center, University of 
Kentucky, Lexington, Kentucky 40536,' and Department of Ophthalmology, Washington University, 
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Syngeneic graft-versus-host disease (SGVHD) has 
been shown to occur in murine syngeneic radiation 
bone marrow chimeras following a short course of 
cyclosporine. To analyze the effector mechanisms 
present in diseased animals, four T cell clones (lD5, 
ID8, ICIO, 2D8) were isolated from the spleens ofC3H1 
HeN mice late in the disease course by cloning on 
irradiated syngeneic spleen cells. These clones were 
CD4+, afJ TCR+ and responded to I_KIl in vitro. In 
addition to I-Ell reactivity, three of the clones exhib-
ited crossreactivity with the superantigen .Mls la (mtv 
7). Clones ID5 and lCIO were found to express TCR V/3 
chains (VfJ4 and V{38.1, respectively), which are nor-
mally present in the T cell repertoire of C3H1HeN mice. 
All SGVHD clones were found to be autoreactive in 
that they responded to syngeneic stimulator cells in 
the absence of xenogeneic serum proteins. To test in 
vivo activity, the !D5 SGVHD clone was injected into 
the hind footpad of mice where it was shown to induce 
footpad swelling in a cell dose-dependent, I·EIl.spe-
cific manner in sublethally irradiated, hut not normal 
mice. Histological analysis indicated that the clone 
induced dermal and subcutaneous edema that corre-
lated directly with injection of lD5 and not the control 
clone. Preliminary experiments suggested that the 
other three autoreactive clones behaved in a similar 
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manner. These data are consistent with the involve-
ment of a self-class II-specific CD4 + T cell in murine 
SGVHD. 
The immunosuppressive agent cyclosporine (CsA)* has 
been shown to induce T cell unresponsiveness (1) and has 
been used clinically and experimentally to prevent graft reo 
jection following solid organ transplantation and graft-ver· 
sus-host disease (GVHD) after bone marrow transplantation 
(BMT [3-6]). Interestingly, upon cessation of CsA treatment 
following autologous or syngeneic BMT in man and rodents, 
a syndrome similar to GVHD has been shown to develop 
(7-15). Syngeneic GVHD (SGVHD) could be adoptively trans-
ferred with T cells from diseased animals into irradiated but 
not normal secondary recipients, suggesting that normal an· 
imals may maintain regulatory mechanism(s) to control au-
toreactivity (7, 8). Three conditions have been shown to be 
required for the induction of SGVHD. Recipient animals had 
to have a thymus (8) and the thymus had to be in the field of 
irradiation (7, 9). Second, recipients had to be irradiated for 
disease induction. Finally, CsA therapy was a prerequisite 
for development of disease in both rats and mice (7, 8, 10). 
The mechanisms by which SGVHD develops upon with-
drawal of CsA therapy remains largely unknown. The thy· 
mus has been shown to be a target organ of CsA, which 
caused the loss of thymic medullary class II-positive cells (9) 
and altered both the positive and negative selection ofimma-
ture thymocytes (14, 15). It has, therefore, been postulated 
that esA-mediated alterations in clonal deletion could be 
responsible for the generation of autoreactive T cells that 
could mediate the development of SGVHD. However, it has 
been shown recently that strain variation in the ability to 
• Abbreviations: esA. cyclosponne: GVHD, grat't-versus.host dis· 
ease: SGVHD. syngeneic grat't.versus.host disease: TCR. T cell re-
ceptor. 
